Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2011; 57(2): 3-13

Interrelation between cardiac pump function disturbances and cardiac contractility after beta-adrenergic hyperstimulation of the heart in rats

Kuz'menko MO, Pavliuchenko VB, Tumanovs'ka LV, Dosenko VIe, Moĭbenko OO

    Bogomoletz Institute of physiology NAS of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz57.02.003


Abstract

The complex of structural and functional changes of myocar­dium was investigated in experiments with rats with chronic P-adrenergic activation for 1 month. We observed substantial attenuation of myocardial pump function, particularly reduction of stroke volume by 38,50% (P<0,01), cardiac output by 42,38% (P<0,01), and ejection fraction by 35,61% (P<0,01). Furthermore, 2-fold increase of end-diastolic left ventricular pressure (P<0,01) and rise of active relaxation constant Tau by 12,91% (P<0,05) were observed. This indi­cates on an impaired diastolic function of the heart that is associated with accumulation of connective tissue elements in myocardium and increase of its end-diastolic stiffness that finally leads to cardiac pump function disturbances. Surpris­ingly, myocardial contractility was considerably augmented not only after the treatment with P-adrenergic agonist but also on the 26th day after drug cessation. This phenomenon is asso­ciated with elevation of dP/dt by 49,9% (P<0,01), 2,5-fold increase of end-systolic elastance (P<0,01) as well as maximal myocardial elastance by 42,53% (P<0,05). It can be explained by compensatory influence of increased contractility that nevertheless failed to maintain adequate cardiac pump func­tion and furthermore it may result in depletion of cardiac energy resource.

Keywords: ?-адренорецепторы, сократимость,насосная функция, сердце.

Full text: (PDF, in Ukrainian)

References

  1. Kazmin SG Cardiodynamics and contractile myocardial activity in cardiac tamponade: Abstract. diss. ... Cand. honey. Sciences. K., 1982.
    2.  
  2. King MO, Pavlyuchenko VB, Tumanovskaya LV, Dosenko VE Investigation of the effect of adrenergic hyperactivation on the formation of cardiogenic depressor reflex in rats . Fiziol Zh.  . 2010. 56, N 2. p.102-103.
    3.  
  3. Meerson FZ Myocardium with hyperfunction, hypertrophy and heart failure. M., Medicine, 1965. 320 p.
    4.  
  4. Moĭbenko AA, Kaz'minSG, Sagach VF. Contractility and contractile activity of the myocardium. . Fiziol Zh. . 1984. 30, N 3. P.333-345.
    5.  
  5. Merkulov GA Course of pathohistological technique. L., Medicine, 1955. 423 p.
    6.  
  6. Svischenko EP, Matova EA Diastolic heart failure . Heart. insufficiency. 2009. N 1. p. 47-54.
    7.  
  7. Stegman OA, Tereshchenko Yu.A. Systolic and diastolic left ventricular dysfunction independent types of heart failure or two sides of the same process? . Cardiology. 2004. N 2. p. 82-86.
    8.  
  8. Anwar A., Schlbter K.D., Heger J., Piper H.M., Euler G. Enhanced SERCA2A expression improves contrac­tile performance of ventricular cardiomyocytes of rat under adrenergic stimulation . Pflug. Arch. 2008. 457,N 2. P.485-491. CrossRef PubMed
    9.  
  9. Brooks W.W., Conrad C.H. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates . Comp. Med. 2009. 59,N 4. P.339-343.
    10.  
  10. Burkhoff D., Mirsky I., Suga H. Assessment of sys­tolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers . Amer. J. Physiol. Heart Circ. Physiol. 2005. 289, N 2. P.501-512. CrossRef PubMed
    11.  
  11. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure . N. Engl. J. Med. 1984. 311,N 13. P.819-823. CrossRef PubMed
    12.  
  12. Dorn G.W. II Novel pharmacotherapies to abrogate postinfarction ventricular remodeling . Nat. Rev. Cardiol. 2009. 6, N 4. P.283-291. CrossRef PubMed
    13.  
  13. Eckhart A.D., Koch W.J. Transgenic studies of cardiac adrenergic receptor regulation . J. Pharmacol. Exp. Ther. 2001. 299, N 1. P. 1-5.
    14.  
  14. Ferreira A.J., Oliveira T.L., Castro M.C., Almeida A.P., Castro C.H., Caliari M.V., Gava E., Kitten G.T., Santos R.A. Isoproterenol-induced impairment of heart func­tion and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991 . Life Sci. 2007. 81,N 11. P.916-923. CrossRef PubMed
    15.  
  15. Flanagan E.T., Buckley M.M., Aherne C.M., Lainis F., Sattar M., Johns E.J. Impact of cardiac hypertro­phy on arterial and cardiopulmonary baroreflex con­trol of renal sympathetic nerve activity in anaesthetized rats . Exp. Physiol. 2008. 93, N 9. P.1058-1064. CrossRef PubMed
    16.  
  16. Grimm D., Holmer S.R., Riegger G.A., Kromer E.P. Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat . Cardiovasc. Pathology. 1999. 8,N 6. P.315-323. CrossRef  
  17. Grimm M., Brown J.H. Beta-adrenergic receptor sig­naling in the heart: role of CAMKII . J. Mol. Cell. Cardiol. 2010. 48. N 2. P.322-330. CrossRef PubMed PubMedCentral
    18.  
  18. Hata J.A., Williams M.L., Koch W.J. Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization . J. Mol. Cell. Cardiol. 2004. 37,N 1. P.11-21. CrossRef  
  19. Heather L.C., Catchpole A.F., Stuckey D.J., Cole M.A., Carr C.A., Clarke K. Isoproterenol induces in vivo functional and metabolic abnormalities: similar to those found in the infarcted rat heart . J. Physiol. Pharmacol. 2009. 60, N 3. P.31-39.
    20.  
  20. Kitagawa Y, Yamashita D., Ito H., Takaki M. The reversible effects of isoproterenol-induced hypertro­phy on in situ left ventricular function in rat hearts . Amer. J. Physiol. Heart Circ. Physiol. 2004. 287, N 1. P.277-285. CrossRef PubMed
    21.  
  21. Kralova E., Mokran T., Murin J., Stankovicova T. Elec­trocardiography in two models of isoproterenol-in­duced left ventricular remodeling . Physiol. Res. 2008. 57, Suppl. 2. P.83-89.
    22.  
  22. Kudej R.K., Iwase M., Uechi M., Vatner D.E., Oka N., Ishikawa Y, Shannon R.P., Bishop S.P., Vatner S.F. Effects of chronic beta-adrenergic receptor stimulation in mice . J. Mol. Cell. Cardiol. 1997. 29, N 10. P.2735-2746. CrossRef PubMed
    23.  
  23. Lee S., Schwinger R. H., Brixius K. Genetically changed mice with chronic deficiency or overexpression of the v-adrenoceptors what can we learn for the therapy of heart failure? . Pflugers Arch. 2008. 455, N 5. P. 767-774. CrossRef PubMed
    24.  
  24. Lyon A. R., Rees P., Prasad S., Poole-Wilson P. A., Harding S.E. Stress (Takotsubo) cardiomyopathy a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning . Cardiovasc. Medicine. 2008. 5, N 1. P.22-29. CrossRef PubMed
    25.  
  25. Murad N., Tucci P.J. Isoproterenol-induced hypertro­phy may result in distinct left ventricular changes . Clin. Exp. Pharmacol. Physiol. 2000. 27, N 5-6. P.352-357. CrossRef PubMed
    26.  
  26. Nakajima-Takenaka C, Zhang G.X., Obata K., Tohne K., Matsuyoshi H., Nagai Y, Nishiyama A., Takaki M. Left ventricular function of isoproterenol-induced hypertrophied rat hearts perfused with blood: mechani­cal work and energetics . Amer. J.Physiol. Heart Circ. Physiol. 2009. 297, N 5. P.1736-1743. CrossRef PubMed
    27.  
  27. Osadchii O.E., Norton G. R., McKechnie R., Deftereos D., Woodiwiss A. J. Cardiac dilatation and pump dys­function without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation . Amer. J. Physiol. Heart Circ Physiol. 2007. 292, N 4. P.1898-1905. CrossRef PubMed
    28.  
  28. Osadchii O.E. Cardiac hypertrophy induced by sus­tained v-adrenoreceptor activation: pathophysiologi­cal aspects . Heart Fail. Rev. 2007. 12, N 1. P.66-86. CrossRef PubMed
    29.  
  29. Pacher P., Nagayama T., Mukhopadhyay P., Bbtkai S., Kass D.A. Measurement of cardiac function using pres­sure-volume conductance catheter technique in mice and rats . Nat. Protoc. 2008. 3, N 9. P.1422-1434. CrossRef PubMed PubMedCentral
    30.  
  30. Satoh H., Tateishi H., Uchida T. Takotsubo-type car­diomyopathy due to multivessel spasm. In: Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure. Ed. Kodama K. Tokyo: Kagakuhyouronsya Co, 1990. P.56-64.
    31.  
  31. Segers P., Georgakopoulos D., Afanasyeva M., Cham­pion H.C., Judge D.P., Millar H.D., Verdonck P., Kass D.A., Stergiopulos N., Westerhof N. Conductance catheter-based assessment of arterial input impedance, arterial function, and ventricular-vascular interaction in mice . Amer. J. Physiol. Heart Circ. Physiol. 2005. 288, N 3. H1157-1164. CrossRef PubMed
    32.  
  32. Serra A.J., Santos M.H., Bocblini D.S., Antfnio E.L., Levy R.F., Santos A.A., Higuchi M.L., Junior J.A., Magalhfles F.C, Bara'na V.G., Krieger J.E., Tucci P.J. Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity . J. Physiol. 2010. 588,N 13. P.2431-2442. CrossRef PubMed PubMedCentral
    33.  
  33. Song Y.H., Li B.S., Chen X.M., Cai H. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and 9 activity and myocardial apoptosis in rats with congestive heart failure . Int. J. Mol. Med. 2008. 21, N 1. P.117-124. CrossRef  
  34. Spindler M., Saupe K.W., Christe M.E., Sweeney H.L., Seidman C.E., Seidman J.G., Ingwall J.S. Diastolic dysfunction and altered energetics in the alpha-MHC403. + mouse model of familial hypertrophic cardiomyopathy . J. Clin. Invest. 1998. 101, N 8. P.1775-1783. CrossRef PubMed PubMedCentral
    35.  
  35. Suga H. Ventricular energetics . Physiol. Rev. 1990. 70, N 2. P.247-277. CrossRef PubMed
    36.  
  36. Suga H. How we view systolic function of the heart: Emax and PVA. In: Systolic and diastolic function of the heart. Ed. Ingels N.B. Amsterdam: IOS Press and Ohmsha. 1995. P.215-225.
    37.  
  37. Sunagawa K, Maughan WL, Sagawa K. Optimal arterial resistance for the maximal stroke work studied in iso­lated canine left ventricle . Circulat. Res. 1985. 56, N 4. P.586-595. CrossRef PubMed
    38.  
  38. Takeshita D., Shimizu J., Kitagawa Y., Yamashita D., Tohne K., Nakajima-Takenaka C, Ito H., Takaki M. Isoproterenol-induced hypertrophied rat hearts: does short-term treatment correspond to long-term treat­ment? . J. Physiol. Sci. 2008. 58, N .3. P.179-188. CrossRef PubMed
    39.  
  39. Webb I.G., Nishino Y, Clark J.E., Murdoch C, Walker S.J., Makowski M.R., Botnar R.M., Redwood S.R., Shah A.M., Marber M.S. Constitutive glycogen syn­thase kinase-3a. b activity protects against chronic v-adrenergic remodelling of the heart . Cardiovasc. Res. 2010. 87N 3. P.494-503. CrossRef PubMed PubMedCentral
    40.  
  40. Zhang G.X., Kimura S., Nishiyama A., Shokoji T., Rahman M., Yao L., Nagai Y, Fujisawa Y, Miyatake A., Abe Y Cardiac oxidative stress in acute and chronic isoproterenol-infused rats . Ibid. 2005. 65 N 1. P.230-238. CrossRef PubMed
    41.  
  41. Zhang G.X., Ohmori K., Nagai Y., Fujisawa Y., Nishiyama A., Abe Y, Kimura S. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxi­dative stress in mice . J. Mol. Cell. Cardiol. 2007. 42,N 4 P.804-811. CrossRef PubMed
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.